BNC Korea Co, Ltd
256840 | KO
Overview
Corporate Details
- ISIN(s):
- KR7256840000
- LEI:
- Country:
- South Korea
- Address:
- 대구광역시 달서구 성서공단로11길 62 대구테크노파크 벤처공장 1호관 405호(사무실),502호, 503호, 206호, 대구광역시
- Website:
- http://www.bnckorea.co.kr
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Legal Proceedings Report
기타경영사항(자율공시) (의약품 회수·폐기 및 잠정 제조중지 등 명령 취소 소송 1심 판결)
|
Korean | 10.7 KB | ||
| 2025-08-26 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (CL-N, N 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 12.6 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.6 MB | ||
| 2025-07-21 00:00 |
Regulatory Filings
투자판단관련주요경영사항 (Cutegel 중국 국가약품감독관리국(NMPA) 품목허가 획득)
|
Korean | 8.4 KB | ||
| 2025-07-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.0 KB | ||
| 2025-05-30 00:00 |
Regulatory Filings
기타경영사항(자율공시)
|
Korean | 6.4 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.5 MB | ||
| 2025-04-29 00:00 |
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 16.5 KB | ||
| 2025-04-08 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 107.2 KB | ||
| 2025-03-31 00:00 |
AGM Information
정기주주총회결과
|
Korean | 19.9 KB | ||
| 2025-03-21 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 25.3 KB | ||
| 2025-03-21 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 2.1 MB | ||
| 2025-03-12 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 195.0 KB | ||
| 2025-03-12 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 195.4 KB |
Automate Your Workflow. Get a real-time feed of all BNC Korea Co, Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for BNC Korea Co, Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BNC Korea Co, Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370
South Korea
067370
Develops novel oncology/antiviral drugs and commercializes generic pharmaceuticals in Canada.
United States of America
SBFM
United States of America
SBFM
Develops and commercializes therapies for CNS diseases like epilepsy, migraine, and ADHD.
United States of America
SUPN
United States of America
SUPN
Provides medical device coatings, vascular products, and components for diagnostic tests.
United States of America
SRDX
United States of America
SRDX
Develops engineered cancer drugs like ADCs using a cell-free protein synthesis platform.
United States of America
STRO
United States of America
STRO
/other/Swedencare_AB_publ-logo.png){kind=logo}
Develops and markets premium health supplements and pharmaceuticals for cats, dogs, and horses.
Sweden
SECARE
Sweden
SECARE
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden
SOBI
Sweden
SOBI
Acquires and commercializes specialty drugs for unmet needs in Japan and the Asia-Pacific region.
Japan
4582
Japan
4582
Biotech developing oral therapies to resolve inflammation in diseases like rheumatoid arthritis.
Sweden
SYNACT
Sweden
SYNACT
Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.
United Kingdom
SNG
United Kingdom
SNG